Country: United States
Language: English
Source: NLM (National Library of Medicine)
DESLORATADINE (UNII: FVF865388R) (DESLORATADINE - UNII:FVF865388R)
Paddock Laboratories, LLC
DESLORATADINE
DESLORATADINE 5 mg
PRESCRIPTION DRUG
Abbreviated New Drug Application
DESLORATADINE- DESLORATADINE TABLET, FILM COATED PADDOCK LABORATORIES, LLC ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE DESLORATADINE TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR DESLORATADINE TABLETS. DESLORATADINE TABLETS FOR ORAL USE INITIAL U.S. APPROVAL: 2001 INDICATIONS AND USAGE DESLORATADINE TABLETS ARE INDICATED FOR: (1) • • DOSAGE AND ADMINISTRATION DOSAGE (BY AGE): (2) ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OVER: (2) • DOSAGE FORMS AND STRENGTHS • CONTRAINDICATIONS • WARNINGS AND PRECAUTIONS • ADVERSE REACTIONS • TO REPORT SUSPECTED ADVERSE REACTIONS, CONTACT PERRIGO AT 1-866-634-9120 OR FDA AT 1-800-FDA-1088 OR www.fda.gov/medwatch. USE IN SPECIFIC POPULATIONS • • SEE 17 FOR PATIENT COUNSELING INFORMATION AND FDA-APPROVED PATIENT LABELING. REVISED: 1/2014 FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 1.1 SEASONAL ALLERGIC RHINITIS 1.2 Perennial Allergic Rhinitis 2 DOSAGE AND ADMINISTRATION 2.1 Adults and adolescents 12 years of age and over SEASONAL ALLERGIC RHINITIS: relief of nasal and non-nasal symptoms in patients 12 years of age and older. (1.1) PERENNIAL ALLERGIC RHINITIS: relief of nasal and non-nasal symptoms in patients 12 years of age and older. (1.2) DESLORATADINE TABLETS – ONE 5 MG TABLET ONCE DAILY DESLORATADINE TABLETS – 5 MG (3) HYPERSENSITIVITY (4, 6.2) HYPERSENSITIVITY REACTIONS INCLUDING RASH, PRURITUS, URTICARIAL, EDEMA, DYSPNEA, AND ANAPHYLAXIS HAVE BEEN REPORTED. IN SUCH CASES, STOP DESLORATADINE TABLETS AT ONCE AND CONSIDER ALTERNATIVE TREATMENTS. (5.1) THE MOST COMMON ADVERSE REACTIONS (REPORTED IN ≥2% of adult and adolescent patients with allergic rhinitis and greater than placebo) were pharyngitis, dry mouth, myalgia, fatigue, somnolence, dysmenorrhea. (6.1) RENAL IMPAIRMENT: DOSAGE ADJUSTMENT IS RECOMMENDED (2.5, 8.6, 12.3) HEPATIC IMPAIRMENT: DOSAGE ADJUSTMENT IS RECOMMENDED (2.5, 8.7, 12.3) 2.5 Adults with Hepatic or Renal Impairment 3 Read the complete document